Amarin Corporation

Amarin Corporation is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular diseases. Amarin's primary candidate, AMR101, is currently being studied in two concurrent pivotal Phase 3 trials. These trials are investigating the efficacy of AMR101 in reducing triglycerides in patients with very high triglyceride levels (> 500 mg/dl) and in patients with mixed dyslipidemia who are on statin therapy. Amarin’s cardiovascular program leverages the company’s expertise in lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular diseases.